微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2024, Vol. 16 ›› Issue (2): 229-237.doi: 10.3969/j.issn.1674-5671.2024.02.14

• 临床研究 • 上一篇    下一篇

基于医院登记的78 046例恶性肿瘤患者生存报告

  

  1. 广西医科大学附属肿瘤医院疾病流程管理办公室；深圳市微著网络科技有限公司；广西医科大学附属肿瘤医院妇瘤科
  • 出版日期:2024-04-25 发布日期:2024-05-08

A survival report of 78,046 patients with malignant tumor from a hospital?based cancer registry database

  • Online:2024-04-25 Published:2024-05-08

PDF (PC)

66

赞

摘要： 目的 基于医院登记的恶性肿瘤患者随访资料，以真实世界数据侧面反映地区恶性肿瘤的治疗效果。 方法 纳入2011年1月1日至2020年12月31日于广西医科大学附属肿瘤医院确诊的恶性肿瘤住院患者，共78 046例包括17种恶性肿瘤的随访数据质量符合要求纳入研究。通过医院疾病管理系统及电话随访等方式收集生存随访信息，随访统计时间截至2023年6月30日。应用寿命表法估计各瘤别的1年、3年和5年总生存（overall survival，OS）率，分别对不同性别、年龄组、民族、临床分期及首次治疗时间患者的生存情况进行分析。结果 收治的前5位恶性肿瘤依次为肝癌（14 672例）、肺癌（10 878例）、女性乳腺癌（9 430例）、结直肠癌（6 895例）、宫颈癌（6 250例）。17种恶性肿瘤患者的1、3、5年OS率分别为76.3%、58.6%和51.4%，其中男性患者5年OS率低于女性（39.9% vs 63.1%）。各癌种OS的总体趋势均随着年龄增加而下降，其中≤44岁、45~54岁、55~64岁、65~74岁和≥75岁年龄组患者的5年OS率分别为64.0%、59.6%、52.7%、44.9%和35.7%。相比2011—2015年，2016—2020年肝癌、肺癌、女性乳腺癌、结直肠癌、鼻咽癌、淋巴瘤患者的5年OS率均明显升高（均P<0.05）。不同临床分期恶性肿瘤患者的生存状况差异有统计学意义（均P<0.01），其中Ⅰ~Ⅱ期患者的5年OS率高于Ⅲ~Ⅳ期患者（82.2% vs 43.4%）。肝癌、肺癌、女性乳腺癌、鼻咽癌、结直肠癌、宫颈癌中壮族患者的5年OS率较汉族患者明显降低（均P<0.05）。结论 肝癌、肺癌是主要的收治癌种，恶性肿瘤患者中总体50%以上可以获得超过5年的生存期，不同癌种、年龄、性别、民族的恶性肿瘤患者生存状况存在明显差异，应持续实施规范、创新、多学科联合及精准的肿瘤临床治疗和早诊早治手段，以进一步改善患者的生存情况。

关键词: 恶性肿瘤, 生存率, 医院登记, 随访

Abstract: Objective To reflect current cancer treatment effect with real world data based on the follow⁃up data of patients with malignant tumors from a hospital⁃based cancer registry database. Methods The hospitalized patients with malignant tumors diagnosed in the Guangxi Medical University Cancer Hospital from January 1 of 2011 and December 31 of 2020 were enrolled, and a total of 78,046 cases with 17 types of malignant tumors had the follow⁃up data meeting the quality requirements. The survival follow⁃up information was collected from the disease management system records and by telephone visits, and the follow⁃up statistics were conducted as of June 30, 2023. Life table was use to evaluate the 1⁃year, 3⁃year and 5⁃year overall survival (OS) rates of each disease, the survivals of patients with respect to gender, age group, nationality, clinical stages and the first treatment time were analyze. Results The top 5 cancers were liver cancer (14,672 cases), lung cancer (10,878 cases), female breast cancer (9,430 cases), colorectal cancer (6,895 cases) and cervical cancer (6,250 cases). The 1⁃year, 3 year and 5⁃year OS rates of patients with 17 typs of malignant tumors were 76.3%、58.6% and 51.4%, respectively. The 5⁃year OS rate of male patients was lower than that of female patients (39.9% vs 63.1%). The overall trend of OS for each cancer species decreased with increase of age, and the 5⁃year OS rates were 64.0%, 59.6%, 52.7%, 44.9%, and 35.7% for the age groups of ≤44, 45-54, 55-64, 65-74, and ≥75, respectively. Compared with those in the period of 2011—2015, the 5⁃year OS rates of patients with liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer and lymphoma were significantly higher (all P<0.05) during 2016—2020. There was significant difference in survival among patients with different clinical stages of malignant tumors (all P<0.01), and the 5⁃year OS rate of patients with stageⅠ-Ⅱ was higher than that of patients with stage Ⅲ-Ⅳ (82.2% vs 43.4%).The 5⁃year OS rate of patients with liver cancer, lung cancer, female breast cancer, nasopharyngeal carcinoma, colorectal cancer and cervical cancer in Zhuang nationality was significantly lower than that in Han nationality (all P<0.05). Conclusions Liver cancer and lung cancer are the main types of cancer to be treated, and more than 50% of patients with malignant tumors can survive for more than 5 years. The survival status of patients with malignant tumors is significantly different with respect to tumor type, age, gender and nationality. The standardized, innovative, multidisciplinary and precise clinical treatment and the early diagnosis and treatment of cancer should be continuously implemented to further improve the survival of patients.

Key words: Malignant tumor, Survival rate, Hospital-based registry, Follow-up

中图分类号: 

  • 引用本文

    陈丽君, 梁秀妹, 吴芸, 卢香宁, 谢刚林, 阳志军. 基于医院登记的78 046例恶性肿瘤患者生存报告[J]. 中国癌症防治杂志, 2024, 16(2): 229-237.

    CHEN Lijun, LIANG Xiumei, WU Yun, LU Xiangning, XIE Ganglin, YANG Zhijun. A survival report of 78,046 patients with malignant tumor from a hospital?based cancer registry database[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(2): 229-237.